Podcasts about clia

Interim CEO of ASCP and host Dr. Ali Brown sits down with Dr. Eric Konnick and Michelle Campbell, MLS(ASCP) to discuss lessons learned from the latest efforts to place laboratory developed tests under FDA oversight. For listeners unfamiliar with LDTs, they begin by establishing what LDTs are and what their value to the lab and patient safety are before debunking common misunderstandings cited by patient advocacy groups regarding their accuracy, validity, and the transparency with which they're developed. They go on to define what FDA oversight would mean for laboratories in terms of cost, time, and labor, contextualizing these added costs in ongoing workforce shortages in the lab. They close their conversation by spotlighting which efforts ASCP and similar organizations made to advocate for the lab were most successful, and describe alternative strategies for updating laboratory regulations, such as modernizing CLIA. 

在離開舒適圈之前，你不知道待在舒適圈裡有多爽。聽到網路迷因傳來的這句話，然後呢？其實離開舒適圈，才知道外面的舒適圈更爽。在職涯的旅途上，每個人多少都經歷過跌跌撞撞、起起伏伏，但終究會走到自己喜歡的位置上發光發熱。往往偶而放慢腳步，蹲下來才能跳的更高 （但是也別蹲到腳麻了喔！） 本集邀請在猶他州新創Teiko.bio擔任Chief Scientific Officer的鄭立群博士，來跟大家分享協助打造新創公司的經驗、以及如何在激烈的競爭環境中安內壤外，帶領團隊走在穩定成長的道路上。另外，立群在職涯探索過程中的心路歷程也同樣不藏私的和聽眾們分享，期待能帶給同樣在生技產業奮鬥的大家帶來暖暖的正能量！  

Dr. Tomasz Beer, MD, chief medical officer at Exact Sciences, joins HealthLeaders for a discussion on the clinical research behind Cancerguard tests and how they enable health systems to detect multiple deadly cancers early, streamline diagnostic workflows, and deliver proactive, value-based care. Information presented is not clinical, diagnostic, or treatment advice for any particular patient. Providers should use their clinical judgement and experience when deciding how to diagnose or treat patients. Exact Sciences does not recommend or endorse any particular course of treatment or medical choice. The Cancerguard test was developed, and the performance characteristics validated by Exact Sciences Laboratories following College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) regulations. This test has not been cleared or approved by the US Food and Drug Administration. The test is performed at Exact Sciences Laboratories. Exact Sciences Laboratories is accredited by CAP, certified under CLIA regulations, and qualified to perform high-complexity clinical laboratory testing.

Dr. Pedro Barata and Dr. Aditya Bagrodia discuss the evolving landscape of testicular cancer survivorship, the impact of treatment-related complications, and management strategies to optimize long-term outcomes and quality of life. TRANSCRIPT:  Dr. Pedro Barata: Hello and welcome to By the Book, a podcast series from ASCO that features engaging conversations between editors and authors of the ASCO Educational Book. I'm Dr. Pedro Barata. I'm a medical oncologist at University Hospitals Seidman Cancer Center and associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also an associate editor of the ASCO Educational Book. We all know that testicular cancer is a rare but highly curable malignancy that mainly affects young men. Multimodal advances in therapy have resulted in excellent cancer specific survival, but testicular cancer survivors face significant long term treatment related toxicities which affect their quality of life and require surveillance and management. With that, I'm very happy today to be joined by Dr. Aditya Bagrodia, a urologic oncologist, professor, and the GU Disease Team lead at UC San Diego[KI1]  Health, and also the lead author of the recently published paper in the ASCO Educational Book titled, "Key Updates in Testicular Cancer: Optimizing Survivorship and Survival." And he's also the host of the world-renowned BackTable Urology Podcast. Dr. Bagrodia, I'm so happy that you're joining us today. Welcome. Dr. Aditya Bagrodia: Thanks, Pedro. Absolutely a pleasure to be here. Really appreciate the opportunity. Dr. Pedro Barata: Absolutely.  So, just to say that our full disclosures are available in the transcript of this episode.  Let's get things started. I'm really excited to talk about this. I'm biased, I do treat testicular cancer among other GU malignancies and so it's a really, really important topic that we face every day, right? Fortunately, for most of these patients, we're able to cure them. But it always comes up the question, "What now? You know, scans, management, cardio oncology, what survivorship programs we have in place? Are we addressing the different survivorship piece, psychology, fertility, et cetera?" So, we'll try to capture all of that today. Aditya, congrats again, you did a fantastic job putting together the insights and thoughts and what we know today about this important topic. And so, let's get focused specifically about what happens when patients get cured. So, many of us, in many centers, were fortunate enough to have these survivorship programs together, but I find that sometimes from talking to colleagues, they're not exactly the same thing and they don't mean the same thing to different people, to different institutions, right? So, first things first. What do you tell a patient perhaps when they ask you, "What can happen to me now that I'm done with treatment for testicular cancer?" Whether it's chemotherapy or just surgery or even radiation therapy? "So, what about the long term? What should I expect, Doctor, that might happen to me in the long run?" Dr. Aditya Bagrodia: Totally. I mean, I think that question's really front and center, Pedro, and really appreciate you all highlighting this topic. It was an absolute honor to work with true thought leaders and the survivorship bit of it is front and center, in my opinion. It's really the focus, you know, we, generally speaking should be able to cure these young men, but it's the 10, 15, 20 years down the way that they're going to largely contend with. The conversation really begins at diagnosis, pre-education. Fortunately, the bulk of patients that present are those with stage one disease, and even very basic things like before orchiectomy, talking about a prosthetic; we know that that can impact body image and self esteem, whether or not they decide to receive it or not. Actually, just being offered a prosthetic is important and this is something, you know, for any urologist, it's kind of critical. To discussing fertility elements to this, taking your time to examine the contralateral testicle, ask about fertility problems, issues, concerns, offer sperm banking, even in the context of a completely normal contralateral testicle, I think these things are quite important.  So if it's somebody with stage one disease, you know, without going too far down discussing adjuvant therapy and so forth, I will start the conversation with, "You know, the testes do largely two things. They make testosterone and they make sperm." By and large, patients are going to be able to have acceptable levels of testosterone, adequate sperm parameters to maintain kind of a normal gonadal state and to naturally conceive, should that be something they're interested in. However, there's still going to be, depending on what resource you look at, somewhere in the order of 10-30% that are going to have issues. Where I think for the stage one patients, it's really incumbent upon us is actually to not wait for them to discuss their concerns, particularly with testosterone, which many times can be a little bit vague, but to proactively ask about it every time. Libido, erectile quality, muscle mass maintenance, energy, fatigue. All of these are kind of associated symptoms of hypogonadism. But for a lot of kids 18-20 years old, it's going to be something insidious that they don't think about. So, for the stage one patients, it absolutely starts with gonadal function. If they are stage two getting surgery, I think the counseling really needs to center around a possibility for ejaculatory dysfunction. Now, for a chemotherapy-naive, nerve-sparing RPLND, generally these days we should be able to preserve ejaculatory function at high volume centers, but you still want to bring that up and again kind of touch base on thinking about sperm banking and so forth before the operation, scars, those are things I think worth talking about, small risk of ascites. Then, I think the intensity of potential long term adverse effects really ramps up when we're talking about systemic therapy, chemotherapy. And then there's of course some radiation therapy specific elements that come up. So, for the chemotherapy bits of it, I really think this is going to be something that can be a complete multi-system affected intervention. So, anxiety, depression, our group has actually shown using some population resources that even suicidality can be increased among patients that have been treated for germ cell tumor. You know, really from the top down, tinnitus, hearing changes, those are things that we need to ask about at every appointment. Neuropathy, sexual health, that we kind of talked about, including ED (erectile dysfunction), vertigo, dizziness, Raynaud's phenomenon, these are kind of more the symptoms that I think we need to inquire about every time. And what we do here and I think at a lot of survivorship programs is use kind of a battery of validated instruments, germ cell tumor specific, platinum treated patient specific. So we use a combination of EORTC questions and PROMIS questions, which actually serves as like a review of systems for the patient, also as a research element. We review that and then depending on what might be going on, we can dig into that further, get them over to colleagues in audiology or psychology, et cetera.  And then of course, screening for the hypertension, hyperlipidemia, metabolic syndrome with basically you or myself or somebody kind of like us serving, many times it's the role of the PCP, just making sure we're checking out, you know, CBC, CMP, et cetera, lipid parameters to screen for those kind of cardiac associated issues along with secondary malignancies. Dr. Pedro Barata: So that's super comprehensive and thorough. Thank you so much. Actually, I love how you break it down in a simple way. Two functions of the testes, produce testosterone and then, you know, the problem related to that is the hypogonadism, and then the second, as you mentioned, produce sperm and of course related to the fertility issues with that.  So, let's start with the first one that you mentioned. So, you do cite that in your paper, around 5-10% of men end up getting, developing hypogonadism, maybe clinical when they present with symptoms, maybe subclinical. So, I'm wondering, for our audience, what kind of recommendations we would give for addressing that or kind of thinking of that? How often are you ordering those tests? And then, when you're thinking about testosterone replacement therapy, is that something you do immediately or are there any guidelines into context that? How do you approach that? Dr. Aditya Bagrodia: So, just a bit more on digging into it even in terms of the questions to ask, you know, "Do you have any decrease in sexual drive? Any erectile dysfunction? Are your morning erections still taking place? Has the ejaculate volume changed? Physically, muscle mass, strength? Have you been putting on weight? Have you noticed increase in body fat?" And sometimes this is complicated because there's some anxiety that comes along with a cancer diagnosis when you're 20, 30 years old, multifactorial, hair loss, hot flashes, irritability. Sometimes they'll, you know, literally they'll say, "You know, my significant other or partners noticed that I'm really just a little bit labile." So I think, you know, there's the symptoms and then checking, usually kind of a gonadal panel, FSH, LH, free and total testosterone, sex hormone binding globulin, that's going to be typically pretty comprehensive. So if you've got symptoms plus some laboratory work, and ideally that pre-orchiectomy testosterone gives you some delta. If they started out at an 800, 900, now they're 400, that might be a big change for them. And then, when you talk about TRT (Testosterone Replacement Therapy) recommendations, you know, Pedro, yourself, myself, we're kind of lucky to be at academic centers and we've got men's health colleagues that are ultra experts, but at a high level, I would say that a lot of the TRT options center around fertility goals. Exogenous testosterone treats the low T, but it does suppress gonadal function, including spermatogenesis. So if that's not a priority, they can just get TRT. It should be done under the care of a urologist, a men's health, an endocrinologist, where we're checking liver chemistries and CBCs and a PSA and so forth. If they're interested in fertility preservation, then I would say engaging an endocrinologist, men's health expert is important. There's medications even like hCG, Clomid, which works centrally and stimulate the gonadal access. Niche scenarios where they might want standard TRT now, and then down the way, 5, 7 years, they're thinking about coming off of that for fertility purposes, I think that's really where you want to have an expert involved because there's quite a bit of nuance there in recovery of actual spermatogenesis and so forth.  To kind of summarize, you got to ask about it. Checking it is, is not overly complicated. We do a baseline pre-orchiectomy and at least once annually, you can tag it in with the tumor markers, so it's not an extra blood draw. And if they have symptoms of course, kind of developed, then we'll move that up in the evaluation. Dr. Pedro Barata: Got it. And you also touch base on the fertility angle, which is truly important. And I'm just curious, you know, a lot of times many of us might see one, two patients a year, right, and we forget these protocols and what we've got to do about that.  And so I'm interested to hear your thoughts about when you think about fertility, and how proactive you get. In other words, who do you refer for the fertility clinic, for a fertility preservation program? You know, do all cases despite getting through orchiectomy or just the cases that you're going to, you know you're going to seek chemotherapy at some point? What kind of selection or it depends on the chemo, like how do you do that assessment about the referral for preservation program that you might have available at UCSD? Dr. Aditya Bagrodia: Yeah, I mean I feel really fortunate to sit on the NCCN Testis Cancer Guidelines. It's in there that fertility counseling should be discussed prior to orchiectomy. So 100% bring it up. If there are risk factors, undescended testicles, previous history of fertility concerns, atrophic contralateral testicle, anything on the ultrasound like microlithiasis in the contralateral testicle, you kind of wanna get it there. And then again, there's kind of niche scenarios where you're really worried, maybe get a semen analysis and it doesn't look that good, arrange for the time of orchiectomy to have onco-testicular sperm extraction from the, quote unquote, "normal" testis parenchyma. You know, I think you have to be kind of prepared to go that route and really make sure you're doing this completely comprehensively.  So pre-orchiectomy all patients. Don't really push for it too hard if they've got a contralateral testicle, if they've had no issues having children. There's some cost associated with this, sperm banking still isn't kind of covered even in the context of men with cancer. If they've got risk factors, absolutely pre-orchiectomy. Pre-RPLND, even though the rates of ejaculatory dysfunction at a high-volume center should be low single digits, I'll still offer it. That'd be a real catastrophe if they were in that small proportion of patients and now they're going to be reliant on things like intrauterine insemination, where it becomes quite expensive.  Pre-chemo, everybody. That's basically a standard these days where it should be discussed and it's kind of amazing currently, even if you don't have an accessible men's health fertility clinic, there are actually companies, I have no vested interest, Fellow is one such company where you can actually create an account, receive a FedEx semen analysis and cryopreservation kit, send it back in, and all CLIA certified, it's based out of California. The gentleman that runs it, is a urologist and very, very bright guy who's done a lot of great stuff for testis cancer. So, even for patients that are kind of in extremis at the hospital that kind of need to get going like yesterday, we still discuss it. We've got some mechanisms in place to either have them take a semen analysis over to our Men's Health clinic or send it off to Fellow, which I think is pretty cool and that even extends to some of our younger adolescent patients where going to a clinic and providing a sample might be tricky.  So, I think bringing it up every stage, anytime there's an intervention that might be offered, orchiectomy, chemo, surgery, radiation, it's kind of incumbent on us to discuss it. Dr. Pedro Barata: Gotcha. That's super helpful. And you also touch base on another angle, which is the psychosocial angle around this. You mentioned suicidal rates, you mentioned anxiety, perhaps depression in some cases as well as chronic fatigue, not necessarily just because of the low testosterone that you can get, but also from a psychological perspective. I'm curious, what do the recommendations look like for that? Do these patients need to see a social worker or a psychologist, or do they need to answer a screening test every time they come to see us and then based on that, we kind of escalate, take the next steps according to that? Do they see a psychologist perhaps every so often? How should that be managed and addressed? Dr. Aditya Bagrodia: It's an excellent question and again, these can be rather insidious symptoms where if you don't really dig in and inquire, they can be glossed over. I mean, how easy to say, "Your markers look okay, your scans look okay. See you in six months," and keep it kind of brief. First off, I think bringing it up proactively and normalizing it, that, "This may be something that you experience. Many people do, you're not alone, there's nothing kind of wrong with you." I also think that this is an area where support groups can be incredibly useful. We host the Testicular Cancer Awareness Foundation support group here. They'll talk about chemo brain or just like a little bit of an adjustment disorder after their diagnosis. Support groups, I think are critical. As I mentioned, we have a survivorship program that's led by a combination of our med oncs, myself on the uro-onc side, as well as APPs, where we are systematically asking about essentially the whole litany of issues that may arise, including psychosocial, anxiety, depression, suicidality. And we've got a nice kind of fast path into our cancer center support services for these young men to meet with a psychologist. If that isn't going to be sufficient, they can actually see a psychiatrist to discuss medications and so forth. I do think that we've got to screen for these because, as anticipated from diagnosis, those first 2 years, we see a rise. But even 10, 15 years out, we note, compared to controls, that there is an increased level of anxiety, depression, suicidality that might not just take place at that initial acute period of diagnosis and treatment. Dr. Pedro Barata: Really well said. Super important.  So I guess if I were to put all these together, with these really amazing advances in technology, we all know AI, some of us might be more or less aware of biomarkers coming up, including microRNA for example, and others, like as I think of all these potential long term complications for these patients, look at the future, I guess, can we use this as a way to deescalate treatment where it's not really necessary, as a way to actually prevent some of these complications? Like, how do we see where we're heading? As we manage testicular cancer, let's say, within the next 5 or 10 years, do you think there's something coming up that's going to be different from what we're doing things today? Dr. Aditya Bagrodia: Totally. I mean, I think it's as exciting as a time as there's ever been, you know, maybe notwithstanding circa 1970s when platinum was discovered. So microRNAs, which you mentioned, you know, there's a new candidate biomarker, microRNA-371. We are super excited here at UCSD. We actually have it CLIA-certified available in our lab and are ordering these tests for patients kind of in their acute stage, you know, stage one and surveillance, stage two, post-RPLND, receiving chemotherapy. And essentially this is a universal germ cell tumor specific biomarker, except for teratoma, suffice it to say 90% sensitive and specific. And I think it's going to change the way that we diagnose and manage patients. You know, pre-orchiectomy, that's pretty straightforward. Post-orchiectomy, maybe we can really decrease the number of CT scans that are done. Maybe we can identify those patients that basically have occult disease where we can intervene early, either with RPLND or single cycle chemo. Post-RPLND, identify the patients who are at higher risk of relapse that may benefit from some adjuvant therapy. In the advanced setting, look at marker decline for patients in addition to standard tumor markers. Can we modulate their systemic therapy?  So, the international interest is largely on modifying things. There's really cool clinical trials that we have for stage one patients, that treatment would be prescribed based on a post-orchiectomy microRNA. I think the microRNAs are really exciting. Teratoma remains an outstanding question. I think this is where maybe ctDNA, perhaps some radiomics and advanced imaging processing and incorporating AI may allow us to safely avoid a lot of these post-chemo RPLNDs. And then identification using SNPs and so forth of who might be most susceptible to some of the cardiac toxicity, autotoxicity and personalizing things in that way as well. Dr. Pedro Barata: Super exciting, right, what's about to come? And I agree with you, I think it's going to change dramatically how we manage this disease.  This has been a pleasure sitting down with you. I guess before letting you go, anything else you'd like to add before we wrap it up? Dr. Aditya Bagrodia: Yeah, first off, again, just want to thank you and ASCO for the opportunity. And it's easy enough to, I think, approach a patient with the testicular germ cell tumor as, "This is an easy case. We're just going to do whatever we've done. Go to the guidelines that says do X, Y, or Z." But there's so much more nuance to it than that. Getting it done perfectly, I think, is mandatory. Whatever we do is an impact on them for the next 50, 60, 70 years of their life. And I found the germ cell tumor community, people are really passionate about it. If you're ever uncertain, there's experts throughout the country and internationally. Ask somebody before you do something that you can't undo. I think we owe it to them to get it perfect so that we can really maximize the survivorship and the survival like we've been talking about. Dr. Pedro Barata: Aditya, thanks for sharing your fantastic insights with us on this podcast. Dr. Aditya Bagrodia: All right, Pedro. Fantastic. Appreciate the opportunity. Dr. Pedro Barata: And also, thank you to our listeners for your time today. I actually encourage you to check out Dr. Bagrodia's article in the 2025 ASCO Educational Book. We'll post a link to the paper in the show notes. Remember, it's free access online, and you can actually download it as well as a PDF. You can also find on the website a wealth of other great papers from the ASCO Educational Book on key advances and novel approaches that are shaping modern oncology.  So with that, thank you everyone. Thank you, Aditya, one more time, for joining us. Thank you, have a good day. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:         Dr. Pedro Barata  @PBarataMD   Dr. Aditya Bagrodia @AdityaBagrodia Follow ASCO on social media:         @ASCO on X (formerly Twitter)         ASCO on Bluesky        ASCO on Facebook         ASCO on LinkedIn         Disclosures:      Dr. Pedro Barata:  Stock and Other Ownership Interests: Luminate Medical  Honoraria: UroToday  Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon  Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas  Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck   Dr. Aditya Bagrodia: Consulting or Advisory Role: Veracyte, Ferring  

Jane Middleton from The Authentic Travel Company talks about her journey from Aviation into the cruise industry. Hear how she discovered CLIA and how one webinar changed her life as she fell in love with expedition and Antarctica. Jane also shares her tips for other agents looking to sell Expedition cruises and also what she thought when she visited Svalbard during CLIA's expedition showcase in 2025.

La Corte internazionale di giustizia ribadisce a Israele - nel primo pronunciamento del processo per crimini di guerra - che è obbligatorio far entrare gli aiuti umanitari, anche tramite Unrwa, bandita da Gaza. I lavoratori dell'azienda Leonardo di Grottaglie scrivono all'azienda chiedendo di non vendere più armi a Israele.Per la prima volta, il presidente ucraino Vlodimyr Zelensky chiede pubblicamente di cominciare le trattative con la Russia a partire dalle attuali linee di confine, seguendo le richieste di Trump. Intanto Rewilding Ukraine - durante la guerra - ha rinaturalizzato oltre 13mila ettari di terre umide, utilizzate anche dai soldati per decomprimere.Negli Stati Uniti, la conta dei danni da eventi climatici estremi ammonta a oltre 100 miliardi di dollari, solo per il primo semestre del 2025. Per la prima volta, l'evento più costo non è un uragano ma un incendio, con ben 61 miliardi di dollari di danni per le fiamme a Los Angeles a inizio anno.

In this fascinating and much-anticipated conversation, Susan sits down once again with the one and only Dr. Cam McDonald, CEO and Chief Educator of pH360, mentor, and longtime friend, to explore one of the hottest topics in the health world today: AI in medicine.We're diving deep into the difference between using general AI tools like ChatGPT to make health decisions versus precision medical AI systems designed specifically for clinical use, like CLIA, the cutting-edge AI developed by pH360.Dr. Cam breaks down how CLIA has been built over 15 years of real-world medical data from 140 countries, offering a truly individualized, evidence-based approach that considers your genes, environment, biology, and lifestyle, not just generic “one-size-fits-all” answers from the internet.In this episode:Why using ChatGPT for health advice can be risky, and sometimes dangerousHow CLIA's advanced data modeling transforms AI into a medical precision toolThe three V's that make data trustworthy: Volume, Veracity, and VarietyHow CLIA integrates with your pH360 profile, labs, DNA, and lifestyle data for truly personalized insightsReal-world results from Susan's clients, from dramatic cholesterol drops to reversing early kidney diseaseSusan also shares her own story of using CLIA to optimize her thyroid health, improve sleep, and even lower her biological age, proving that the right technology, used correctly, can truly transform human potential.If you've ever turned to ChatGPT or Google for health advice, you need to hear this one.This conversation will completely change how you think about AI, medicine, and the future of personalized wellness.Listen in to discover: Why not all AI is created equal — and how precision health technology like CLIA is rewriting the future of healthcare.Learn more about our guest Dr. Cam McDonald:Dr Cam McDonald is a leader, educator, PhD scholar and internationally recognised speaker on personalised and precision health. As a key executive & education leader at Precision Health Alliance – his mission is to eliminate chronic disease and pain by 2050, and having ‘healthy' and ‘resilient'  as the norm. Dr Cam is an exercise physiology, accredited practising dietitian, PhD Scholar, a Fellow of the Australasian Society of Lifestyle Medicine, an experienced clinician and is an international leader in the application of personalised health, epigenetics. His focus is to educate individuals on how the whole environment impacts physical and mental health and disease. Dr Cam leaves an indelible mark on the audience through his ability to simplify the complexity of health science, infuse hope and stimulate action.RESOURCES:Connect with Dr. Cam McDonald:Instagram: https://www.instagram.com/drcammcdonald/Website: https://precisionhealthalliance.org/Find all of Kate and Susan's Resources and links in the show notes: https://healthyawakening.co/2025/10/20/episode85Connect with Susan: https://healthyawakening.co/Connect with Kate: https://theradiantlifeproject.com/Visit the website: healthyawakening.co/podcastFind listening links here: https://healthyawakening.co/linksP.S. Want reminders about episodes? Sign up for our newsletter, you can find the link on our podcast page! https://healthyawakening.co/podcast

Lumos Diagnostics Senior Vice President Paul Kase joined Steve Darling from Proactive to discuss a major milestone for the company — the signing of an agreement with WellStreet Urgent Care to accelerate testing and reimbursement pathways for its FebriDx® rapid host-response test. The initiative will be launched through WellStreet's joint venture with Piedmont Urgent Care in Atlanta, Georgia, marking a key step toward broader US adoption. Under the program, FebriDx will be deployed at a Piedmont Urgent Care site handling approximately 50 respiratory-infection patients per day, providing Lumos with high-quality operational data on workflow efficiency, patient outcomes, and payer engagement. Kase explained that WellStreet will procure FebriDx through PHASE Scientific and submit reimbursement claims for each test, while Pro-spectus will oversee billing data management and claims analysis. This collaborative approach is designed to generate real-world evidence to support the development of comprehensive reimbursement and coverage policies with major U.S. insurers. Pending the granting of a CLIA waiver for FebriDx, Lumos and WellStreet plan to expand the program nationwide, leveraging insights from the pilot to guide a potential rollout across more than 140 WellStreet urgent care locations across the United States. Kase added, “This partnership represents a major step in bringing FebriDx to scale in the U.S. healthcare system. By validating operational efficiency and demonstrating reimbursement viability, we're building the foundation for widespread clinical adoption of a test that helps physicians quickly differentiate between bacterial and viral infections.” #proactiveinvestors #lumosdiagnosticsholdings #asx #ldx #otc #ldxhf #LumosDiagnostics #FebriDx #PointOfCareTesting #HealthcareInnovation #UrgentCare #DiagnosticTesting #InfectionDetection #AntibioticStewardship #MedicalTechnology #ProactiveInvestors

See all the Healthcasts at https://www.biobalancehealth.com/healthcast-blog You will learn: What holds up new treatments for diseases and conditions How long the FDA sits on a known safe medical medication before it is released to the public. Why safe and effective drugs are NOT approved by the FDA Why doctors are forced to use medications off label How you can help During my 44 years of medical practice, I have encountered conditions for which there is no approved medication or surgical treatment available as recognized by the American College of OBGYN or the FDA. This situation can present challenges both for physicians managing these patients and for individuals seeking relief from their symptoms. This issue is not often addressed on Dr Oz, in the news, or at medical conferences. For many conditions, physicians wait for the development of approved medications or treatments, and in the meantime may inform patients that there is currently no treatment or cure available. Some doctors may attribute a patient's concerns to aging, stating that it is a universal experience. While this may be accurate, such explanations may not provide comfort to patients seeking solutions to their symptoms. This lack of helpful guidance can discourage individuals from seeking medical care when they feel their concerns are not acknowledged. This seems to result from insurance companies prioritizing cost savings by minimizing patient care.  Every year insurance companies decrease what they pay doctors for their services, while their expenses go up, and the Government requires more and more work behind the scenes like HIPPA, OSHA, and Clia requirements that costs more to deliver the same service.  If you have a problem with the time your doctor spends with you then blame the insurance companies whose profits rise every year…Soon doctors will do what I do and only take cash.  The practice of medicine is not working in a free market. While insurance limits the prescriptions of medication to those meds that are FDA Approved, the FDA and medical specialty colleges often delay approval of new, low-risk treatments for up to 20 years after their effectiveness is demonstrated. This lengthy process should be reconsidered to treat people who are ill and suffering, now. There is plenty of research in the medical journals that explain the safety of new and effective treatments that can save peoples' lives that are not FDA approved yet. The FDA is not interested in expediting the release of medication/ devices quickly to those people who need help now. They drag out the testing of a medicine that has been effective for years and may or may not approve it. On the flip side they have approved many drugs that later are found to have severe side effects, and they just change the warnings on the medication inserts. They don't take them off the market except in severe cases. Drugs that have worked treating patients successfully are being used but are not FDA approved. These “grandfathered drugs” don't need to go through the testing that new drugs go through because they work with few well-known risks. I use many if these medications because they are inexpensive for my patients and are often more effective than new meds for the same problem. One of the drugs that the FDA has not had to approve is Armour Thyroid, a natural thyroid replacement. My experience with treatments not approved by the FDA Armour Thyroid: Armour Thyroid (AT) has been prescribed by doctors to replace thyroid hormones for about 100 years. It is natural, made from Pig thyroid. It only comes from “medical Pigs” that are raised for medical purposes.  We use medical pigs for skin grafts, and other parts of the pig to treat human diseases like heart valve replacements.  Armour Thyroid is composed of the four thyroid hormones that humans make: T4, T3, T2, T1. The synthetic thyroid replacement, Synthroid/levothyroxine is only T4.  The active form of thyroid is T3, and it requires an enzyme to convert T4 into T3. If a person can't convert T4 into active T3 then nothing improves except the blood levels of T4, and TSH. The majority of women cannot convert T4 into T3. Therefore, if they take Synthroid or levothyroxine and their doctor only checks their TSH level and not the level of free T3 and free T4 to see if the Thyroid is working, then women are told that they are healed, yet they know they are not because none of their low thyroid symptoms are resolved. When this happens, doctors tell female patients that it is all in their heads and dismiss us when we tell them we are not cured with this synthetic T4 medication. Yet Synthroid is a chemical, and AT is natural from medical pigs, so the FDA is trying to Bann the only drug that has successfully treated millions of women. PS. Synthroid was not tested on women like many other drugs that were passed through the FDA before 2014! If you think this is a small problem, think again. Thyroid hormones are vital to human life, and the thyroid gland requires Iodine in the diet. The Midwest US has no Iodine in the soil or water. Therefore, this area is overburdened with hypothyroidism. I have been on AT for 50 years without complication and I have prescribed it thousands of times ever since I went into private practice.  AT works to relieve the symptoms of hypothyroidism for women and men, and it works better for women that the “new” drug Synthroid/levothyroxine, which is FDA approved. You ask how could the FDA approve a drug that doesn't successfully treat women? It is because Synthroid was not tested on women!  Until 2014 the FDA did not test women in the required drug trials.  AT works for us (women), Levothyroxine does not. Now the FDA wants to ban AT. It is not approved because it was around for decades before they started testing medications like they do now, and the history of successful treatment should stand on its own merit! Example 2: Bio-Identical Hormones BIH:  BIHs had not been approved by the FDA until recently and there was no announcement that they are now approved for women who have hormone deficiency symptoms or postmenopausal symptoms. Most doctors and women who have been afraid of the only hormones that can help them, bioidentical hormones, haven't yet been told that NOW, FINALLY the medical colleges and the FDA finally have quietly approved BI hormones.  There are no pure estradiol and pure testosterone pellets that are made by a drug company for women. My patients get their estradiol and testosterone pellets from a compounding pharmacy.  I have been prescribing BIH since 1985 without FDA approval because the oral estrogen formulations that were available at pharmacies caused weight gain and put women at high risk for blood clots. Non-oral BI hormones have fewer risks than FDA approved estrogens.  I waited more than 45 years for the FDA to approve BI hormones for treatment of women.  All those women in the last 45 years who were taking FDA approved estradiol and those who couldn't tolerate them have been harmed by FDA goals of never approving compounded or bio-identical hormones.  The delay has harmed 50% of American women. Example #3 Devices for Weight Loss I was involved in the discovery and testing of a unique device that stimulated acupuncture points with a TENS-unit-type patch connected to your cell phone for easy adjustment of your hunger or “fullness”. The FDA requires testing to approve any new device so the group of investors I was part of had to invest thousands of dollars for a device we already knew worked. The FDA told the investigators of all new devices who they should test, who they can't have in the study, and how long the testing should take. I found their parameters for the study of this device to be unrealistic. The women in our test group could not be taking hormones of any kind (birth control, ERT, HRT), and could not be on antidepressants, could not have diabetes or insulin resistance or be on any drug that assisted in weight loss. These women subjects had to be a certain BMI (level of obesity) and had to be tested repeatedly with weight and body composition measurements None of my patients who needed weight loss could participate.  Most GYN patients are on some medication or supplement, so the FDA made this study of our device so narrow that REAL WOMEN weren't tested! Sadly, we lost many women in the control group from the study because they were NOT losing weight while the ones on the device were obviously dropping pounds, so we had trouble maintaining test subjects. The testing phase of this simple device took 7 years! Our device works and no one will ever know about it or be able to use this non-medicinal weight loss device because when the FDA rejects your device you will be breaking the law if you produce and sell it directly to the public. It has no side effects or dangers..it just controls the amount you eat with stimulation of an acupuncture point. There are many ways to change this situation, and it takes years and billions of dollars to change the whole system of bringing treatments to patients quickly.  I'm afraid I won't see a revolution of the way we bring medicines and devices to market during my lifetime. Currently there is a 17-year delay between proving a drug or device works for a particular illness or condition and when it becomes available to doctors and patients. So what do we do in the meantime?  I seek treatments for patients who are unresponsive to traditional medicine by reading journals like Life Extension, that inform doctors and patients alike about new effective solutions for common medical complaints and diseases that the FDA has ignored or stymied with endless drug trials.  Life Extension Magazine highlights studies on new medications for diseases without an FDA approved solution and publicizes diagnostic tests often overlooked by mainstream publications because they are not yet FDA approved. The medical journals I read (New England Journal of Medicine, JAMA, Menopause, Metabolism and Endocrinology, Journal of Age management, to name a few) offer treatments for orphan diseases or even common problems that haven't been blessed by the FDA. It takes an average of 17 years from the culmination of research on a new drug, test or device until it is approved for use by the public! At the end of this Blog, I will give you a link to make your voice heard by signing a petition to shorten the approval of new treatments and medications from the average of 17 years to 3 years! My patients don't have time to wait for relief, and that may be the case for you as well. If you want to do something to help, please click this link and let the FDA know how you feel. Please sign a Petition to enact an amendment to the FOOD, DRUG and COSMETIC ACT, by going to: https://age-reversal.net/fda/

Crystal Cruises, VP President, Trade Sales UK & EMEA Luke Smith sat down with CLIA's Andy Harmer to talk about joining Crystal Cruises , his goals for making them the most trade friendly and easy to do business with ultra-luxury cruise line. Updates coming to their travel agent portals and how to get in touch with him and his team.

Debido a la necesidad de mantener una programación dinámica y adaptada a los tiempos

Standard blood tests barely scratch the surface. Ryan Smith shares how TruDiagnostic's TruAge & TruHealth tests use over 1,700 biomarkers from just a drop of blood to measure biological age, hormone health, immunity & more. Go beyond standard labs & start bioharmonizing with cutting-edge precision so you can make decisions that actually impact how you feel & age. Meet our guest Ryan Smith studied Biochemistry at Transylvania University before founding Tailor Made Compounding, which became one of the fastest-growing healthcare companies in the U.S. After exiting in 2020, he launched several ventures, including TruDiagnostic, a CLIA-certified lab specializing in methylation-based diagnostics for longevity & preventive health. TruDiagnostic leads the field with one of the largest private epigenetic databases, over 13,000 patients, & active participation in 30+ clinical research studies. Ryan remains a key figure in advancing functional medicine through innovative health data solutions. Thank you to our partners Outliyr Biohacker's Peak Performance Shop: get exclusive discounts on cutting-edge health, wellness, & performance gear Ultimate Health Optimization Deals: a database of of all the current best biohacking deals on technology, supplements, systems and more Latest Summits, Conferences, Masterclasses, and Health Optimization Events: join me at the top events around the world FREE Outliyr Nootropics Mini-Course: gain mental clarity, energy, motivation, and focus Key takeaways Biological age gives a clearer picture of health risk than birthdate by showing how your body is actually aging Lifestyle basics like exercise, clean eating, stress reduction & social connection remain top tools for aging well Some biological age tests are more reliable thanks to stronger prediction power & actionable results Longevity interventions can now be ranked using technology that tracks measurable improvements over time Leading tests don't just score your age but give clear next steps to improve healthspan & lifespan DNA methylation data offers biomarker proxies that sometimes outperform traditional blood tests Methylation-based tests bring better precision & consistency than standard lab results affected by daily shifts Immune system strength plays a major role in aging by influencing inflammation & clearing damaged cells Supplement & lifestyle tracking tools now show whether specific changes are actually improving key health markers TruAge tests work well for most while biohackers may benefit more from deeper panels like the TruHealth test Episode Highlights 3:29 What Biological Age Really Tells You 10:12 Inside TruDiagnostic's Testing Framework 11:39 Key Lifestyle & Supplement Insights from the Data 15:10 How to Interpret Your Report & Take Action 30:12 Understanding Your Immune & Metabolic Health 45:29 Practical Application & Future of Epigenetic Testing Links Watch it on YouTube: https://youtu.be/MykPl4fZ3Sc  Full episode show notes: outliyr.com/221 Connect with Nick on social media Instagram Twitter (X) YouTube LinkedIn Easy ways to support Subscribe Leave an Apple Podcast review Suggest a guest Do you have questions, thoughts, or feedback for us? Let me know in the show notes above and one of us will get back to you! Be an Outliyr, Nick

Seabourn VP, UK, Europe & EMEA Lynn Narraway sat down with CLIA's Andy Harmer to share her decades of experiences in the cruise industry. She also highlights the role of people driven individuals who work in cruise industry and why it remains as important as event even in the era of Ai. Hear how Lynn feels the industry, demographic and her role has changed. Lynn also tells about what's attracting those “New to Cruise” and also those “New to Seabourn” guests. Not forgetting Seabourn moments, Lynn shares some inspirational and emotional Seabourn moments they have given guests and also locals to the regions their ultra-luxury ships visit.

Hannah Went is the Co-Founder of TruDiagnostic, a leading health data company and CLIA-certified laboratory that specializes in epigenetic testing and research.. Hannah is also the creator and host of the Everything Epigenetics Podcast. She is a molecular biologist by day and content creator by night and speaks with the most knowledgeable physicians and researchers in the world. Hannah is passionate about empowering people to take control of their health and wellness, and to discover new ways to enhance their overall performance. Epigenetic Experts & 
Aging Authorities At TruDiagnostic, we are firm believers that harnessing the power of epigenetic data can help the world live longer and healthier lives! We are a group of innovative doctors, researchers, clinicians, molecular biologists, biotechnology leaders, and diagnostic professionals. LEARN MORE, ORDER: https://www.trudiagnostic.com/ LISTEN TO FULL PODCDAST EPISODE: https://conciergemedicinetoday.net/podcast About Our Guest, Hannah Went, Co-Founder | TruDiagnostic  Hannah has a lifelong passion for longevity and breakthrough, disruptive technologies that drive radical improvement to the human condition. She attended the University of Kentucky and graduated with a degree in Biology. During that time, she had multiple research internships studying cell signaling and cell biology. After graduation, she worked for the International Peptide Society as their Director of Research and Content. Through work in the integrative medicine industry, Hannah saw an opportunity for methylation based age diagnostics and started TruDiagnostic in 2020. TruDiagnostic is a company focusing on methylation array-based diagnostics for life extension and preventive healthcare serving functional medicine providers.  TruDiagnostic has a commitment to research with over 30 approved clinical trials investigating the epigenetic methylation changes of longevity and health interventions. Since TruDiagnostic's inception, they have created one of the largest private epigenetic health databases in the world with over 75,000 patients tested to date. Hannah has since created Everything Epigenetics where she shares insights on how DNA regulation has an impact on your health. Connect with and Learn More about TruDiagnostic ... (https://www.trudiagnostic.com/)

En una muy interesante entrevista hablamos con Marco Ferraz, Presidente de CLIA, Cruise Lines International Association, por sus siglas en inglés, entidad que nuclea el quehacer de la industria de cruceros en todo el mundo. Con el hablamos de la actualidad de la industria a nivel global y los desafíos para la región donde cada vez más usuarios utilizan este tipo de barcos para vacacionar en distintos destinos. En la nota, habló del crecimiento de la industria en la región e hizo hincapié en el potencial que tiene en la Argentina.Turismocero radio es el programa radial del site ww.turismocero.com, que desde 2011 informa sobre la actualidad del turismo en toda Latinoamérica, emitiéndose semanalmente en radios de distintas localidades de Argentina, Uruguay Perú.

Call to OrderRoll CallApproval of Minutes: April 17, 2025 May 28, 2025 – Special Assembly: Board of Equalization Approval of AgendaReports of Officials and Committees: Mayor's Report Assembly Committee Reports Treasurer's Report Manager's Report Communications to the Assembly: Correspondence Hear Citizens PresentOrdinances, Resolutions, & Proclamations: Public Hearing, Second Reading, and Adoption of Ordinance No 25-08: Amending the FY25 Budget to Appropriate Funds for a Seasonal Firefighting Position to Support Emergency Services in Dyea (Public Hearing was opened and closed on May 15, 2025; Active Motion for Adoption) Public Hearing and Adoption of Resolution No. 25-16R: Updating the Fifteen-Acre Site Plan Near the Klondike Highway and Directing the Creation of a Public Dog Park Unfinished BusinessNew Business: Consideration of Mayoral Resignation and Declaration of Vacancy Approval of Pedestrian Crowding and Vehicle Traffic Congestion on Broadway Proposal: Phase 1 Award of Garden City RV Park Utilities Design Contract Approval of Rock Slope Summer Monitoring Proposal Award of Ore Peninsula Redevelopment Pile Anodes ContractApproval of Ore Basin Dredging Support Services Proposal Approval of Ore Dock Electrical Construction Support Services Proposal Approval of Broadway Dock Fuel Header Relocation Study Proposal Approval of Station Request to Close Fourth Avenue for Fourth of July Festivities Consideration of Response to Announcement Regarding the Cascade Point Ferry Terminal Consideration of Rescheduling the June 20, 2025 Assembly MeetingMayor and Assembly Discussion ItemsExecutive session: Matters, the immediate knowledge of which would clearly have an adverse effect upon the finances of the public entity, and matters which by law, municipal charter, or ordinance are required to be confidential: Discussion of CLIA v. Municipality of Skagway, Case No. 1JU-25-00628CI AdjournmentPacket

The 2025 NovaUCD Student Enterprise Competition, an intensive 4-week accelerator programme for student entrepreneurs, which is now in its 11th year, has commenced today at University College Dublin (UCD) with 11 early-stage ventures and 22 participating students. The participating ventures are focused on a wide range of business ideas including; sustainable agriculture, robotics, edtech, smart sensing systems for healthcare, sustainable fashion and music. A €3k NovaUCD One to Watch Prize, sponsored by Terra Solar, is available for the overall winning venture at the end of this year's competition. The accelerator programme is run by NovaUCD, the innovation and start-up hub, as a framework to support UCD undergraduate and postgraduate students who want to work together to develop and grow start-up companies. The aim of the accelerator is to assist the students in refining their start-up ideas through a series of structured workshops, including taught content from industry experts, interactive workshops, regular mentoring and pitching sessions. Caroline Gill, Innovation Pathway Manager at NovaUCD who manages the competition said, "Over the next month we will be supporting the participating student entrepreneurs as they begin the process of accelerating their business ideas into early-stage start-ups. A key objective of this annual competition is to provide the students with the skills, the confidence, and the opportunity to further develop their ideas and hopefully in time launch their start-ups in Ireland and even internationally." The 4-week accelerator, which uses the Lean Startup and Business Model Canvas approach, includes a series of structured and interactive workshops delivered by Raomal Perera, Lean Disruptor. Topics such as, customer development; value proposition; working in teams; design thinking; prototyping, environment mapping; financial planning and effective fundraising and pitching, will be covered. At a final workshop, to be held in late-June, the participating ventures will pitch to a judging panel. Based on the evaluation of the presentations an overall winner will be selected and will receive the €3k NovaUCD One to Watch Prize sponsored by Terra Solar. At the end of the 2024 competition physiotherapists Rory Lambe and Ben O'Grady, both then masters students in the UCD School of Public Health, Physiotherapy and Sports Science, were announced as winners of the Tech Sustainability Prize. Clia, their early-stage venture, aims to make a meaningful difference to the lives of people with cardiovascular disease by combining clinical data with wearable technology to improve its management. Rory is now a PhD student and earlier this year to further develop Clia he was one of several UCD students selected to participate in Conception X, a nine-month venture programme in London, focused on supporting PhD students from the UK and across Europe, to turn their research into deep tech start-ups. Fourteen (14) postgraduate and 8 undergraduate students are participating on this year's accelerator programme. Over 80 early-stage ventures and some 200 students have completed NovaUCD Student Enterprise Competitions to date. More about Irish Tech News Irish Tech News are Ireland's No. 1 Online Tech Publication and often Ireland's No.1 Tech Podcast too. You can find hundreds of fantastic previous episodes and subscribe using whatever platform you like via our Anchor.fm page here: https://anchor.fm/irish-tech-news If you'd like to be featured in an upcoming Podcast email us at Simon@IrishTechNews.ie now to discuss. Irish Tech News have a range of services available to help promote your business. Why not drop us a line at Info@IrishTechNews.ie now to find out more about how we can help you reach our audience. You can also find and follow us on Twitter, LinkedIn, Facebook, Instagram, TikTok and Snapchat.

What does it take to stand up for people navigating the complex journey of immigration? Mary Choate knows firsthand as Executive Director of the Center for Legal Immigration Assistance (CLIA) in Lincoln, Nebraska.Founded in 2001, CLIA provides comprehensive legal services to help immigrants and refugees thrive throughout Nebraska. Mary explains why this work matters deeply: "Your neighbors probably have an immigration story they could tell." These are people living in our communities, paying taxes, and contributing to local economies—yet they face significant challenges navigating legal systems, especially amid widespread misinformation.Want to learn more or support CLIA's vital work? Visit www.cliane.org to discover how you can help Nebraska's immigrant communities thrive.Welcome to the Agency for Change podcast.

Everyone loves a good tech strategy session—but how do we make sure those plans don't just sit on a shelf? We're diving into the realities of making strategy happen. Join us for the second installment of Tech Strategy in Action, a series where we dive into exactly that.   Today we will be discussing how CLIA has implemented their newly imagined website based on an enormous amount of user research, led by our guest Jill Straniero, SVP of Digital Solutions and Managing Director of Global Technology. We will discuss how deep user interviews and audience analysis revealed the need to shift from a department-focused approach to an audience-focused digital strategy. The findings helped streamline twelve websites into two distinct ones. The conversation highlights how user research is not just for usability—it's a strategic tool for long-term organizational alignment and smarter tech investments  Hosted by Norma Castrejon, Vice President, Information Technology at the American Osteopathic Association and Rhoni Rakos, Lead Consultant, Digital Strategy at Ellipsis Partners.  Make sure to follow TPAC on LinkedIn: https://www.linkedin.com/company/asae-tpac/ 

J.C. Sheppard, is the Founder of The Fentanyl Test, the world's first FDA-CLEARED, CLIA-waived dip-card test for over-the-counter use, and the world's only Harm Reduction test strip to reach the cutoff level of 1ng/mL which is also the world's only test to not require dilution of any tested substance. China says fentanyl issue is responsibility of the United States

Louise Craddock Oceania Cruises (Director of Sales UK & Ireland) shares her journey into her current role as well as an overview of the Oceania brand. Having been with Oceania Cruises for over 14 years her passion remains as she tells us more about what sets Oceania apart and how they have elevated what they offer their guests onboard and ashore. For those lucky to be joining us at CLIA conference they will get their first chance to catch a glimpse of their latest ship Oceania Vista which will also give agents a taste of what's to come in their upcoming ship Allura. She also has some exciting updates about shorter sailings which can be a great entry point for first time customers looking to experience Oceania. Join the Join the Trader Inside Oceania Cruises UK Facebook group at https://www.facebook.com/share/g/1EXD1z6ZTg/?mibextid=wwXIfr

As you’ll hear in this discussion, it’s Earth Month, and we couldn’t not have an episode about sustainability efforts within travel. Here, host Rebecca Tobin speaks with Paula Vlammings, the chief impact officer of nonprofit Tourism Cares, and Travel Weekly hospitality editor Christina Jekski about some of the hot topics of 2025. Topics we cover: Solutions to overtourism; why travelers don’t want to pay more for green travel initiatives; and whether recent shifts in U.S. policy will have an impact on sustainability efforts. This episode was recorded April 24 and was edited for length and clarity. Episode sponsor: This episode is sponsored by The TTC Tour Brands https://agents.ttc.com/login Related links: Sustainability-minded hotels are staying the course https://www.travelweekly.com/Travel-News/Hotel-News/Sustainability-minded-hotels-staying-the-course Arnie Weissmann’s From the Window Seat column: CLIA: “Regulate us. please!” https://www.travelweekly.com/Arnie-Weissmann/CLIA-Regulate-us-Please From 2024: A focus on overtourism overlooks destinations’ problems: https://www.travelweekly.com/Travel-News/Tour-Operators/Overtourism-focus-misses-destination-problems From 2024: Overtourism solutions: putting residents first https://www.travelweekly.com/Travel-News/Travel-Agent-Issues/Tourism-related-issues-need-right-approach-experts-say Tourism Cares: https://www.tourismcares.org/ Note: This episode is ahead of the news: A column by Christina Jelski on Trina White and the Parkside Hotel & Spa will be published later this week.See omnystudio.com/listener for privacy information.

Feeling exhausted, dealing with brain fog, or noticing unexplained weight gain—even though you're doing all the right things? This episode dives into the surprising root cause behind symptoms often blamed on hormone imbalance or stress. It's something most women overlook, and it could be sabotaging your energy, focus, and sleep. Tune in to uncover what might really be going on beneath the surface—and why your environment could be playing a bigger role than you think.

10:05A – 10:22A (17mins) Weekly: Susie Moore, Deputy Managing Editor, Redstate.com @SmoosieQThe FBI Is Quietly-Behind The Scenes Making America Safe Again 10:41 – 10:56 (15mins) J.C. Sheppard, Founder of The Fentanyl Test Republican AGs urge Trump to crack down on obscure 'loophole' cartels use to flood US with fentanyl Fentanyl is the #1 killer of Americans aged 18-49 and the fastest growing killer of children under the age of 14… J.C. Sheppard, is the Founder of The Fentanyl Test, the world's first FDA-CLEARED, CLIA-waived dip-card test for over-the-counter use, and the world's only Harm Reduction test strip to reach the cutoff level of 1ng/mL which is also the world's only test to not require dilution of any tested substance.See omnystudio.com/listener for privacy information.

Episode 130 - Andy Talks with Jos Dewing from explorearth.com by CLIA

10:05 – 10:15 (10 mins) J.C. Sheppard J.C. Sheppard - MAKE AMERICA HEALTHY AGAINFounder of The Fentanyl Test, the world's first FDA-CLEARED, CLIA-waived dip-card test for over-the-counter use, and the world's only Harm Reduction test strip to reach the cutoff level of 1ng/mL which is also the world's only test to not require dilution of any tested substance.Starts by Eliminating the New Face of the Drug Epidemic in the U.S.Canada PM Trudeau Bends the Knee to Trump, Appoints ‘Fentanyl Czar’Fentanyl is the #1 killer of Americans aged 18-49 and the fastest growing killer of children under the age of 14…Fentanyl Has Killed More Americans Than All Previous Wars Combined 10:41 – 10:56 (15mins) Weekly: Drew Thomas Allen @DrewThomasAllen Author, America's Last Stand: Will You Vote to Save or Destroy America in 2024Host of ‘The Drew Allen Show’ podcast VP of client development at Publius PR & Editor of the Publius National Post.columnistSee omnystudio.com/listener for privacy information.

We are well into 2025 so saying Happy New Year is not appropriate anymore. I think now people are asking others how they are doing with their resolutions. I have just one goal this year and that is to learn something new. I'll let you know how I do. Send me your resolutions in the comment section. I am excited for you to listen to my conversation with Dr. Brian Fiske, Chief Scientist for the MJFF. I like to kick off the new year/new season with a medication update. This year we are going to get an update on the research landscape and what it means compared to previous years. There are therapies in various stages of clinical testing using several different therapeutic approaches.  It is exciting to learn about what to expect in the future and how we all can contribute to move things forward faster. Let's learn from Dr. Fiske what we now know about the biology of Parkinson's, genetics and the environment's contribution, the advances in testing for a Parkinson's diagnosis, and where we stand in slowing the progression of the disease. This podcast is sponsored by  CND Life Sciences, home of the Syn-One Test ® - the first commercially available skin-based test to help clinicians diagnose Parkinson's and related disorders. CND Life Sciences supports the care of patients facing the potential diagnosis of a neurodegenerative disease. CND's Syn-One Test® helps clinicians to diagnose suspected synucleinopathies using skin biopsies to detect, visualize, and quantify phosphorylated alpha-synuclein located in nerves in the skin. The Syn-One Test is performed in CND's CLIA-certified and CAP-accredited laboratory located in Scottsdale, AZ.   https://www.michaeljfox.org/state-field https://www.michaeljfox.org/ppmi https://www.michaeljfox.org/trial-finder https://cndlifesciences.com/ https://cndlifesciences.com/syn-one-test/  

Women who believe their implants are making them sick report a wide range of symptoms including extreme fatigue, muscle and joint pain, headache, brain fog, hair loss, rashes, dry mouth and eyes, depression, anxiety, and insomnia. These conditions appear within a few months to several years following surgery and seem to follow a secondary surgery like revision or exchange. However, the exact cause is difficult to pin down because other conditions, like Lyme disease and toxic mold exposure, can cause similar symptoms. Using PCR testing (instead of traditional CLIA-based lab testing), Dr. Rob discovered that over 60% of the breast implants he removed all had one thing in common. Dr. Robert Whitfield describes his methodology for identifying this complicated, misunderstood condition and shares his treatment strategies utilizing nutrition and genetic testing to put his patients on the path to healing. For more healing resources created by Dr. Rob, visit our store - Dr. Rob's Solutions at https://drrobssolutions.myshopify.com (https://drrobssolutions.myshopify.com). Show Highlights: Causes of BII (00:03:56) Biofilm and its significant contribution to breast implant illness cases What is Biofilm? (00:04:56) Explanation of biofilm as a bacterial or fungal contaminant affecting health and inflammation Environmental Factors (00:05:26) Environmental exposures, like mold and Lyme disease, and their role in BII symptoms Gut Health and Immune Response (00:07:43) Gut health's impact on immune function and overall wellness in BII patients Identifying Symptoms and Providers (00:10:12) How to identify symptoms and seek appropriate medical guidance for BII Explant Surgery Options (00:10:12) Overview of surgical options available for patients considering explant surgery Symptom Abatement Timeline (00:11:20) Discussion on the expected timeline for symptom improvement after explant surgery Pathology and Testing (00:12:36) Importance of laboratory analysis in evaluating post-surgery health and contamination Nutritional Support and Genetic Testing (00:13:50) The role of nutrition and genetic predisposition testing in managing BII Cautions on Online Medical Advice (00:15:13) Warnings against seeking medical advice from unqualified sources online Links and Resources Let's Connect... Podcast: https://podcasts.apple.com/gb/podcast/breast-implant-illness/id1678143554 Spotify: https://open.spotify.com/show/1SPDripbluZKYsC0rwrBdb?si=23ea2cd9f6734667 TikTok: https://www.tiktok.com/@drrobertwhitfield?t=8oQyjO25X5i&r=1 IG: https://www.instagram.com/breastimplantillnessexpert/ FB: https://www.facebook.com/DrRobertWhitfield Linkedin: https://www.linkedin.com/in/dr-robert-whitfield-md-50775b10/ X: https://x.com/rob_whitfieldmd Read this article - https://www.breastcancer.org/treatment/surgery/breast-reconstruction/types/implant-reconstruction/illness/breast-implant-illness Shop: https://drrobssolutions.com SHARP: https://www.harp.health NVISN Labs - https://nvisnlabs.com/ Get access to Dr. Rob's Favorite Products below: Danger Coffee - Use our link for mold free coffee - https://dangercoffee.com/pages/mold-free-coffee?ref=ztvhyjg JASPR Air Purifier - Use code DRROB for the Jaspr Air Purifier - https://jaspr.co/ Echo Water - Get high quality water with our code DRROB10 - https://echowater.com/ BallancerPro - Use code DRROBVIP for the world's leader in lymphatic drainage technology - https://ballancerpro.com Ultrahuman - Use code WHITFIELD10 for the most accurate wearable - https://www.ultrahuman.com/ring/buy/us/?affiliateCode=drwhitfield

Dr. Sara Naseri joins me on this episode to talk about the exciting, at home, affordable, easy to use, hemoglobin A1C testing her company QVin had developed that utilizes menstrual blood. Throughout this episode I just kept saying: why weren't we always doing this??!! But the wait is over as QVin can send an FDA approved, CLIA certified and easy to collect test right to your door. H1C is a test we all need and may get pushback from our providers or our insurance about routinely checking it so it's win, win, win, win and has some exciting prospects for future testing on other hormones and possibly even screening for conditions like endometriosis.  Episodes referenced in this show: Dr Brooke Show #398 Making Sense of Blood Sugar Testing: Hemoglobin A1C, Glycomark, CGMs and More   Stuff I Know You Will Love   If you are looking for an expert prescriber for HRT during your perimenopause or menopause journey but are at odds with your local provider being a bit behind current best practices or you simply can't find anyone near you to help, Join MIDI! I've worked with a number of telehealth services in my search for providers that are up to date on modern menopause medicine, have great customer service and who are licensed in all 50 states and I'm so thrilled to have found my provider with MIDI. If you too need help with getting HRT please use this link to check out MIDI! No membership fees and insurance billing available.    Did you know that 95% of women taking a prenatal are still nutrient deficient? The founders of Needed saw this as a big problem and I couldn't agree more! But Needed quickly became a bigger solution to a bigger problem by providing more options for moms and moms to be. Women need so much support during the time from thinking about getting pregnant all the way to having little ones and so often they are left with options that don't address their needs (prenatals that have nutrients in the wrong forms or that they can't take due to nausea) or they are left with low energy, anxiety or even colds/flus while they are pregnant or nursing because there aren't natural products that are considered safe during these times. Needed solved all of these problems as well as created a community of no-guilt, education and support for new moms and moms to be. Learn more about Needed visit thisisneeded.com and save 20% off your first order with code BETTEREVERYDAY at checkout.   Don't miss Organifi Gold Pumpkin Spice! Limited edition of their cozy cup of relaxing deliciousness with turmeric, passionflower, lemon balm and Reishi. Perfect end of a fall evening! Get it before it's gone! Link www.organifi.com/bettereveryday saves you 20%.    Be sure you connect with me in my FREE PRIVATE Facebook group: Hormones & Happiness with Dr Brooke where other amazing, like minded women like YOU are already hanging out! Join us!   Follow Dr Brooke on Instagram and get signed up for my awesome emails here. Seriously,  I write really great emails, or so 1000s of women tell me and I'd like to send you one too. To work with Dr Brooke click here and if you loved this episode please leave a review! 

Research Requires Flexibility: Protease-Free Permeabilization Expands FISH Tissue Applications.-Andrelie Branicky, Shared Laboratory Resources, Lerner Research Institute, Cleveland Clinic, Cleveland, OH Fluorescence in situ hybridization (FISH) visualizes the presence of a specific DNA or RNA sequence in a tissue sample or cell. This method, particularly the mRNA version, detects gene expression when protein might not be present or IHC is impossible. FISH combined with immunohistochemistry enables spatial transcriptomics, which provides significantly more information about the tissue microenvironment. Formalin-fixed paraffin-embedded (FFPE) tissues are the standard for tissue preservation in the clinical world. Most commercial mRNA probe and amplification systems are built around the model of FFPE tissue that can withstand harsh protease permeabilization. In the research world, tissues are fixed in different fixatives for varying times; all at the discretion of the investigator instead of an organization like the CLIA.  Given the wide range of tissue preparations, the HCR automated FISH-ISH protease-free program provides the flexibility to combine  FISH and fluorescent immunohistochemistry on tissue fixed in a variety of ways such as: 10% NBF, Histochoice (a glyoxal-based fixative), and methanol/acetic acid, with only minor changes to the basic protocol. Additionally, the lack of harsh protease pre-treatment maintains tissue integrity and morphology for staining and imaging. 

Priyanka Jain is the co-founder & CEO of Evvy, a precision women's health startup discovering unnoticed biomarkers, starting with the vaginal microbiome. The episode explores the challenges women face in diagnosing and treating conditions like PCOS and the significance of the vaginal microbiome in women's health. Priyanka Jain shares her journey from working in nonprofits to founding Evvy, a company dedicated to improving women's health through better data and diagnostics. Evvy's at-home vaginal microbiome test is the first and only CLIA-certified, mNGS vaginal health test, providing you with the most reliable, comprehensive answers from a single swab. The discussion covers the impact of hormonal imbalances, the role of the vaginal microbiome in preventing infections, and the importance of personalized healthcare. Sponsors: Find SmartMouth at CVS, Walgreens, and Walmart or visit https://smartmouth.com/shemd to snag a special discount on your next SmartMouth purchase. Your mouth will thank you!You can try Freed for free right now by going to https://getfreed.ai. Listeners can use the SHEMD code for $50 off their first month.Timeline is offering 10% off your first order of Mitopure. Go to https://timeline.com/SHEMD.Get 10% off your first order sitewide with code SHEMD at https://OSEAMalibu.com.Nutrafol is offering our listeners ten dollars off your first month's subscription and free shipping when you go to https://Nutrafol.com and enter promo code SHEMD.In This Episode:[2:55] Priyanka Jain's background and journey[5:50] The importance of destigmatizing women's health issues[8:20] Understanding the vaginal microbiome[20:03] Evvy's approach to vaginal health testing[31:02] Insights from Evvy's data on women's health[46:45] Tips for maintaining a healthy vaginal microbiomeKey Takeaways:Consult Before Self-Diagnosing: Always seek professional medical advice or testing before assuming you know the cause of any vaginal symptoms. This helps avoid unnecessary treatments and ensures accurate diagnosis.Be Your Own Advocate: Pay close attention to your body and symptoms. Gather data and information about your health to effectively communicate with healthcare providers, ensuring you receive the best care possible.Understand the Impact of Sexual Activity: Recognize that sexual activity can influence vaginal health. Be mindful of changes in symptoms following sexual encounters and consider discussing these with a healthcare provider if issues arise.Consider Proactive Testing: If you experience recurrent symptoms or are in a specific life stage (e.g., trying to conceive, menopause), consider using at-home testing services like Evvy to monitor your vaginal health and seek guidance when necessary.Avoid Overuse of Antibiotics: Be cautious with antibiotic use, as it can disrupt the natural balance of bacteria. Discuss alternative treatments with your healthcare provider, such as probiotics or lifestyle changes, to maintain a healthy microbiome.About the Guest:Priyanka is the co-founder & CEO of Evvy, a precision women's health startup discovering overlooked biomarkers, starting with the vaginal microbiome. Before founding Evvy, Priyanka was the Head of Product at pymetrics, a startup using behavioral science and AI to make talent matching more effective and fair. She graduated from Stanford University and serves on advisory boards for the XPRIZE Foundation and the United Nations Foundation's Girl Up campaign.Priyanka received her B.S. from Stanford University, where she was a Mayfield Fellow and President of Stanford Women in Business. She has been recognized as Forbes 30 under 30 and Inc's Top Female Founders.EvvyEvvy's at-home vaginal microbiome test is the first and only CLIA-certified, mNGS vaginal health test — providing you with the most reliable, comprehensive answers from a single swab. All results come with a custom plan of clear next steps, along with science-backed education, community, and 1:1 coaching. For eligible tests, they also offer integrative, prescription treatment programs. The results from the Evvy testing kit are analyzed to give users a detailed report on their vaginal health. This report can include information on the balance of different microorganisms, potential health issues, and personalized recommendations for maintaining a healthy microbiome. In addition to its products, Evvy provides educational resources to help women understand their vaginal health better. This includes information on how the vaginal microbiome works, how to interpret test results, and ways to support overall vaginal health. Resource Links:Priyanka's LinkedInInstagram @evvy Company URL www.evvy.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Deepen your medical billing expertise with Part 2 of our series! Learn essential terms including the QW modifier for CLIA-waived tests, understand what upcoding means and why it's prohibited, and master the difference between Local and National Coverage Determinations (LCD/NCD). Schedule a demo with our experts to improve your medical billing operations. With BillPro you can easily beat your competition!

In this insightful episode of the Click&Go Travel Podcast, Paul & Gill are joined by CLIA's Andy Harmer, a leading cruise expert to explore the booming world of cruises, with a special focus on trends shaping the Irish market. From recent industry growth to exciting innovations onboard, we cover everything a curious cruiser might want to know before setting sail.

Join me as I dive into the fascinating world of epigenetics and biological age with TruDiagnostic™ Co-Founder Hannah Went. With a deep-rooted passion for longevity and wellness, Hannah shares insights into how we can measure and influence our biological age. Discover the power of methylation testing, TruDiagnostic's revolutionary health assessments, and actionable strategies to improve health and potentially reverse aging.Hannah Went is the Co-Founder of TruDiagnostic, a pioneering health data company and CLIA-certified laboratory specializing in epigenetic testing and research. As the creator and host of the Everything Epigenetics Podcast, she connects audiences with the world's leading physicians and researchers.A molecular biologist by profession and a content creator by passion, Hannah is dedicated to empowering individuals to take charge of their health and discover innovative strategies to enhance wellness and performance.Website: https://everythingepigenetics.com/X: https://x.com/EverythingEpiFacebook: https://www.facebook.com/EverythingEpigenetics/Instagram: https://www.instagram.com/everythingepigenetics/LinkedIn: https://www.linkedin.com/in/thehannahwent/TruDiagnostic™Website: www.trudiagnostic.comFacebook: https://www.facebook.com/TruDiagnosticInstagram: https://www.instagram.com/trudiagnosticofficial/?hl=enLinkedIn: https://www.linkedin.com/company/trudiagnostic/PODCAST Thank you for listening please subscribe and share! - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - Shop supplements: https://healthybydrjen.shop/ CHECK OUT a list of my Favorite products here: https://www.healthybydrjen.com/drjenfavorites WATCH THIS:https://www.youtube.com/watch?v=2lSyAFy5U4U&list=PLaDiqj0yz1eeCOATXPoUDt8HEJxz1_lfW - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - FOLLOW ME: Instagram :: https://www.instagram.com/integrativedrmom/ Facebook :: https://www.facebook.com/pflegmed Tik Tok :: https://www.tiktok.com/@integrativedrjen YouTube :: https://www.youtube.com/@integrativedrmom - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - FTC: Some links included in this description might be affiliate links. If you purchase a product through one of them, I will receive a commission (at no additional cost to you). I truly appreciate your support of my channel. Thank you for watching! Video is not spons...

Send us a textWhat does the FDA jurisdiction for LDTs mean for the labs? Do they need to worry? How do they need to change the way they operate?In this episode, I talk with Dr. Thomas Nifong, a clinical pathologist and VP of CDX operations at Acrovan Therapeutics, about the recent FDA ruling on laboratory-developed tests (LDTs) issued on May 6th, 2024. We discuss the implications of considering LDTs as medical devices, requiring regulation, and explore the authority of FDA versus CLIA. The conversation also covers historical contexts, practical implications of regulatory changes, and the roles of organizations like CAP, ACLA, and AMP in legal challenges against the FDA. We dive into the differences in requirements between CLIA and FDA, New York's alternative approval route, and potential impacts on lab operations and compliance. Join us for an insightful conversation filled with essential information for those in the field of molecular pathology.00:00 Introduction and Special Guest Announcement00:24 FDA's New Rule on Laboratory Developed Tests (LDTs)01:58 Recording the Podcast: A Casual Lunch Conversation03:47 Understanding FDA's Authority Over Medical Devices08:07 Disputes and Legal Challenges12:03 Practical Implications and Industry Reactions12:47 Understanding FDA's Focus: Safety and Efficacy14:11 The Role of CMS and Medical Necessity14:48 Congressional Involvement and Legal Authority16:06 Impact on Labs and Future LDTs18:33 Quality Systems and Compliance20:16 Modifications and Software Updates21:16 Conclusion and Next StepsSupport the showBecome a Digital Pathology Trailblazer get the "Digital Pathology 101" FREE E-book and join us!

Jason Sheppard, is the Founder of The Fentanyl Test, the world's first FDA-CLEARED, CLIA-waived dip-card test for over- the-counter use. PA Dems say 50 Cents is Worth More Than Their Constituents' Lives

On this episode, I was joined by Devon Campbell, Founder and Managing Director of Prodct. Devon covers the differences between IVDs, companion diagnostics, and precision medicine, the risk management aspects specific to IVDs, and the design, verification, and validation processes involved. Devin shares his extensive experience in both big pharma environments and startups, shedding light on the significant time and resource investments required for successful IVD development. ---------------------------------- Chapters: Exploring In Vitro Diagnostics with Devin Campbell In this episode of the Combinate Podcast, host Subhi Siddek welcomes back Devin Campbell, founder and managing director of Product Know You, to discuss in vitro diagnostics (IVDs). They delve into various aspects of IVD development, including the clinical implications, risk management, and distinctions between companion diagnostics and precision medicine. They also cover regulatory pathways, lab-developed tests, and the rigorous validation processes involved. The conversation aims to demystify the complexities of IVDs for professionals in pharma and medical devices. -------------------------------------- 00:00 Introduction 01:58 Understanding In Vitro Diagnostics (IVDs) 05:26 Companion Diagnostics and Precision Medicine 08:49 Lab Developed Tests (LDTs) 12:39 IVD Development Process 15:27 Risk Management in IVDs 20:17 Clinical Testing and Validation 29:12 Challenges and Considerations in IVDs 37:04 Conclusion and Contact Information Devon Campbell is the Founder, Prodct LLC and Chief Product Officer(CPO), myBiometry. He's launched and exited several MedTech ventures and has worked in large Pharma and large IVD companies in executive roles focusing on engineering and product development. https://www.devonccampbell.com/

Send us a textCurious about how genetic testing can transform your health journey? Join us for a compelling conversation with Dahlia Attia-King, founder and CEO of Panacea, as we uncover the power of predictive genetic testing. Discover how advancements in genetic research, such as the BRCA1 and BRCA2 genes, are not only revolutionizing our understanding of risks for diseases like cancer and heart disease but also empowering individuals to make informed health decisions. We promise you'll walk away with a deeper insight into the role genetics plays in healthcare and the actionable steps you can take to harness this knowledge.Dahlia shares her inspiring journey from aspiring medical student to trailblazing healthcare innovator, revealing the personal motivations behind Panacea's mission to make genetic testing accessible and actionable. We'll explore the technical differences between direct-to-consumer and clinical genetic testing, with a spotlight on technologies like microarray and next-generation sequencing (NGS). Learn about the significant barriers to access, such as insurance coverage and physician hesitancy, and how Panacea is breaking down these obstacles to bring advanced genetic testing directly to the public.Our discussion is enriched with insights from expert genetic counselors, emphasizing the importance of comprehensive clinical guidance alongside genetic testing. We'll also delve into the critical aspects of data privacy, certifications like CLIA and CAP, and the importance of understanding genetic test results. This episode is a must-listen for anyone interested in the future of preventive healthcare, providing a holistic view of how genetic testing can be a powerful tool in managing and mitigating health risks.Panacea's Website: www.seekpanacea.comDiscount Code: DRNOSEWORTHY20You can listen to the Inflammation Nation podcast on Apple Spotify and all other major podcast platform You can also watch on YouTube. Check out my online store for self-learning/DIY programs for thyroid, gut health and detox. You can use this form to reach out and request an Initial ConsultationVisit my LabShop store to self-order the same tests I use with my one-on-one coaching clients. https://labs.rupahealth.com/store/storefront_3GMxe4pSOCIAL LINKSInstagramFacebookTikTok

My guest today is Kelly Craighead, President & CEO of CLIA - one of the travel industry's most important associations representing all things cruises! Before running CLIA, Kelly was the senior government representative for all travel and tourism matters at the Department of Commerce.  So if you're interested in travel trends and what's new in the cruise industry, you're in for a treat!  Kelly and I chat about everything from how millennials are the fastest growing generation for cruise travel, to sustainability on the oceans, to fabulous new destinations you can reach by ship.  Learn more at www.luxtravelinsider.com   Connect with me on Social: Instagram LinkedIn  

Two-time Emmy and three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald, interviewed Sheila Michelle Foye.  Her career began with the Gas Company here in Atlanta just before natural gas was deregulated. She began as an Office Assistant and moved lattice style into mission-critical senior leadership roles within organizations and across industries such as SunTrust Banks (Truist), CapGemini, Accenture, Cox, and healthcare giants such as Morehouse School of Medicine, Piedmont, and Grady. Foye leveraged her corporate knowledge gained over the years to become an award winning, respected successful Entrepreneur in Drug Testing and CLIA-waived Laboratory Testing. Drug Testing was chosen due to her oldest son's murder (age 24), which was drug/ gang violence related and her family history of substance/alcohol abuse that made for a rocky road in life. Nearly two years into the business, Michelle was able to innovate and pivot Precis Screening by establishing a consulting arm that has now assisted more than 3,000 Entrepreneurs and counting. #BEST #AMI #STRAW #SHMSSee omnystudio.com/listener for privacy information.

Two-time Emmy and three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald, interviewed Sheila Michelle Foye.  Her career began with the Gas Company here in Atlanta just before natural gas was deregulated. She began as an Office Assistant and moved lattice style into mission-critical senior leadership roles within organizations and across industries such as SunTrust Banks (Truist), CapGemini, Accenture, Cox, and healthcare giants such as Morehouse School of Medicine, Piedmont, and Grady. Foye leveraged her corporate knowledge gained over the years to become an award winning, respected successful Entrepreneur in Drug Testing and CLIA-waived Laboratory Testing. Drug Testing was chosen due to her oldest son's murder (age 24), which was drug/ gang violence related and her family history of substance/alcohol abuse that made for a rocky road in life. Nearly two years into the business, Michelle was able to innovate and pivot Precis Screening by establishing a consulting arm that has now assisted more than 3,000 Entrepreneurs and counting. #BEST #AMI #STRAW #SHMSSee omnystudio.com/listener for privacy information.

Her career began with the Gas Company here in Atlanta just before natural gas was deregulated. She began as an Office Assistant and moved lattice style into mission-critical senior leadership roles within organizations and across industries such as SunTrust Banks (Truist), CapGemini, Accenture, Cox, and healthcare giants such as Morehouse School of Medicine, Piedmont, and Grady. Foye leveraged her corporate knowledge gained over the years to become an award winning, respected successful Entrepreneur in Drug Testing and CLIA-waived Laboratory Testing. Drug Testing was chosen due to her oldest son's murder (age 24), which was drug/ gang violence related and her family history of substance/alcohol abuse that made for a rocky road in life. Nearly two years into the business, Michelle was able to innovate and pivot Precis Screening by establishing a consulting arm that has now assisted more than 3,000 Entrepreneurs and counting. #STRAW #SHMSSupport the show: https://www.steveharveyfm.com/See omnystudio.com/listener for privacy information.

Her career began with the Gas Company here in Atlanta just before natural gas was deregulated. She began as an Office Assistant and moved lattice style into mission-critical senior leadership roles within organizations and across industries such as SunTrust Banks (Truist), CapGemini, Accenture, Cox, and healthcare giants such as Morehouse School of Medicine, Piedmont, and Grady. Foye leveraged her corporate knowledge gained over the years to become an award winning, respected successful Entrepreneur in Drug Testing and CLIA-waived Laboratory Testing. Drug Testing was chosen due to her oldest son's murder (age 24), which was drug/ gang violence related and her family history of substance/alcohol abuse that made for a rocky road in life. Nearly two years into the business, Michelle was able to innovate and pivot Precis Screening by establishing a consulting arm that has now assisted more than 3,000 Entrepreneurs and counting. #STRAW #SHMSSee omnystudio.com/listener for privacy information.

Diana Azzam, PhD joined us on OsteoBites to discuss her lab's work on functional precision medicine for the treatment of pediatric and adult cancers. This presentation describes the foundational principles of functional precision medicine as applied to pediatric cancers and how major technological improvements as well as an explosive broadening of the cancer pharmacopeia has enabled the bridging of genomics with functional drug testing as clinical decision support tools to impact patient care.Diana Azzam, PhD, is an Assistant Professor and Research Director of the Center for Advancing Personalized Cancer Treatments at Florida International University. She has a Masters in Biochemistry from the American University of Beirut, Lebanon and a PhD in Biochemistry & Molecular Biology from the University of Miami, Florida. Her lab focuses on implementing functional precision medicine (FPM) approaches in adult and pediatric cancer patients that have run out of treatment options. Working with local hospitals including Nicklaus Children's Hospital and Cleveland Clinic Florida, her lab delivers individualized treatment plans based on a patient's cancer genomic profile and ex vivo drug response. She is currently engaged in two clinical studies to assess feasibility and clinical utility of FPM in relapsed/refractory patients with childhood cancer (ClinicalTrials.gov registration: NCT05857969) and adult cancer (ClinicalTrials.gov registration: NCT06024603). Dr. Azzam is working on setting up the first CLIA-certified lab in the State of Florida dedicated for functional cancer drug testing. Her goal is to launch large-scale prospective multi-center randomized clinical trials to better assess efficacy of FPM approaches in the treatment of refractory/relapsed cancers. In parallel, she is working on utilizing FPM as a tool to reduce health disparities in childhood cancer patients from minority populations. She is also integrating a novel machine learning approach to identify specific biomarkers among minority populations that can be targeted using FDA-approved drugs. Her lab also investigates cancer stem cells and how they may result from chronic environmental exposures to toxic metals such as arsenic.After a short presentation on this research, she will take questions from attendees. Share your questions in advance with us at Christina@MIBAgents.org.

Shaun broadcasts LIVE from Cigar Night! PLUS, The Biden Administration has done nothing about the fentanyl flowing over our border and killing our citizens. Jason Sheppard, founder of WimKim Social Media, tells Shaun about his latest project to help save some of the many lives lost to fentanyl - he came up with the first (and only) FDA-approved, CLIA-waived, over the counter fentanyl dip tests. Buy yours today at www.thefentanyltest.com and use promo-code LIBERTY for 10% off your order.   And Shaun talks to Jim Bovard, author of Last Rights: The Death of American Liberty, about the mistake of putting our politicians on a pedastal and the dangers of our new drugged up society.See omnystudio.com/listener for privacy information.

The Biden Administration has done nothing about the fentanyl flowing over our border and killing our citizens. Jason Sheppard, founder of WimKim Social Media, tells Shaun about his latest project to help save some of the many lives lost to fentanyl - he came up with the first (and only) FDA-approved, CLIA-waived, over the counter fentanyl dip tests. Buy yours today at www.thefentanyltest.com and use promo-code LIBERTY for 10% off your order.See omnystudio.com/listener for privacy information.

Ted Karkus CEO & Chairman Of The Board Of ProPhase Labs $PRPH   Ticker: PRPH   Website: https://www.prophaselabs.com/ Bio: Ted Karkus Chairman & CEO of ProPhase Labs Ted Karkus, CEO and Chairman of ProPhase Labs, drives the company's diverse and synergistic businesses with his successful track record in biomedical and health companies. He transformed ID Biomedical's strategy and valuation from $25 million to $1.4 billion sale to GlaxoSmithKline. As CEO of ProPhase Labs, he restructured the go-to-market strategy for the flagship product Cold-EEZE, turned around and significantly grew revenues, ultimately selling it for $50 million to Mylan. ProPhase Labs is a fast-growing biotech, genomics and diagnostics company due to its commitment to growth, innovation, and execution excellence outlined in Ted's high growth roadmap. He pivoted into industry leading CLIA labs, and then further diversified by acquiring genomics leader Nebula Genomics. Constantly innovating, Ted then created ProPhase BioPharma to deliver antivirals, cancer tests and therapeutic cancer compounds. The new acquisitions and legacy businesses work to drive synergistic growth with multi-billion-dollar potential. He holds a BS in Psychology from Tufts University with Magna Cum Laude Honors and an MBA in Finance from Columbia University School of Business with Beta Gamma Sigma Honors. --- Support this podcast: https://podcasters.spotify.com/pod/show/smartmoneycircle/support

Do you know that prostate cancer is the second most prevalent cancer in American men, following skin cancer? A new diagnosis of prostate cancer occurs every two minutes. We are delighted to partner with Oxford Biodynamics for today's episode with Dr. Robert Heaton, who joins us to discuss a ground-breaking new prostate cancer screening test that predicts the risk of prostate cancer with 94% accuracy, using a simple blood test. Dr. Heaton is a board-certified pathologist. He completed his medical training at Georgetown University and then spent the next twenty years in the US Navy. After finishing his residency training in pathology, Dr. Heaton became the Director of Laboratory and Clinical Support Services for the National Naval Medical Center before joining various hospital pathology labs and life sciences companies. He is currently the Laboratory Medical Director for Oxford Biodynamics at their CLIA-certified clinical lab in Maryland, where he oversees the clinical operations of their liquid biopsy blood tests. In today's episode, we dive into the details of the innovative EpiSwitch Prostate Screening test, known as the PSE, designed to confirm the presence of prostate cancer, whether symptoms are present or not. This technological advancement is a game-changer! It empowers urologists by providing a precise tool to assess whether a patient should undergo a biopsy or opt for continued monitoring. Stay tuned to learn how this simple yet powerful tool streamlines the screening process for men struggling with prostate cancer. Disclaimer: The Prostate Health Podcast is for informational purposes only. Nothing in this podcast should be construed as medical advice. By listening to the podcast, no physician-patient relationship has been formed. For more information and counseling, you must contact your personal physician or urologist with questions about your unique situation.   Show Highlights: At what age should men start getting checked for prostate cancer?  What the screening for prostate cancer typically entails The importance of establishing a baseline to monitor how PSA changes over time Dr. Heaton dives into the details of the EpiSwitch PSA test How men can access the EpiSwitch PSA test Dr. Heaton discusses the accuracy of the EpiSwitch PSA test What is the expected turnaround time for the EpiSwitch PSC test results? Dr. Heaton explains the role of the Epi Switch PSA test in different scenarios The revolutionary EpiSwitch Prostate Screening test has remarkable accuracy in predicting prostate cancer risk through a simple blood test. It holds immense promise for men battling prostate cancer by providing urologists with a precise diagnostic tool and offering a streamlined approach for patients facing the complexities of prostate cancer. Links: Follow Dr. Pohlman on Twitter and Instagram - @gpohlmanmd Get your free What To Expect Guide (or find the link on our podcast website)   Join our Facebook group  Follow Dr. Pohlman on Twitter and Instagram  Go to the Prostate Health Academy to sign up.  You can access Dr. Pohlman's free mini webinar, where he discusses his top three tips to promote men's prostate health, longevity, and quality of life here. Oxford BioDynamics: Website LinkedIn  Facebook Twitter: @oxbiodynamics and #OBD Instagram: @oxbiodynamics YouTube: @oxfordbiodynamics PSE: Website LinkedIn Facebook Twitter: (@94percent_com) Instagram: (@get_the_pse)

Unlock the mysteries of your skin's health and aging process in our enlightening conversation with Dr. Barbara Paldus PhD, founder of Codex Labs. Ever wondered how our DNA holds the keys to our body's functions, and how small genetic variants can have substantial impacts on our health? Dr. Paldus takes us on a captivating journey of understanding the world of genetics, exploring how single nucleotide polymorphisms can serve as markers for medical conditions.Get invaluable insights about Codex Labs' innovative DNA kits, 'Decode my Skin DNA' and 'Vitamins DNA,' that offer a comprehensive analysis of genes linked to skin conditions and vitamin deficiencies. Learn about the rigorous process of genetic testing, the evolution of sequencing, and the importance of CLIA certification for quality lab practices. Moreover, we delve into the vital role of medical professionals in prescribing tests and interpreting their clinical utility.We also tackle the fascinating relationship between genes and skin aging, highlighting the essential role vitamins play in skin health. Dr. Paldus shares compelling insights into the impact of specific genes on skin's health, the influence of environmental factors, and the importance of understanding our genetic predispositions. We also weigh the advantages and challenges of genetic testing, emphasizing the value of professional guidance in interpreting results. Pull up a chair and feed your curiosity about the intersection of genetics, skin health, and aging in this engrossing conversation with Dr. Barbara Paldus, PhD.Get 50% off for first 50 customers using the code TRYDNATEST50 when you visit www.codexlabs.comSupport the showFollow The Show On All Socials Using The Tag @skincareanarchy

Aaron Godfrey of My Heritage joins us as we explore DNA, your history, and your heritage. We're also going to hear all about pickle ball evangelism from Christy Largent! Make sure you catch this unusual but exciting broadcast!   Today's Sponsor Amaze Yourself with My Heritage. Uncover your ethnic origins and find new relatives with our simple DNA test. Go to lancewallnau.com/myheritage to save 55% today!    "At MyHeritage, your privacy and the security of your data is as important to us as it is to you. We have made significant investments to ensure that your account and personal details are secured and protected by multiple layers of encryption. All testing is done in our world-leading CLIA-certified, CAP-accredited laboratory in the United States."